← Leaderboards
Sean Vahram Tavtigian
International Agency For Res On Cancer
$12,922,427
Attributed
$19,485,677
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,566,133 · 9
By mechanism
R01$18,288,318 · 6
P01$4,080,456 · 1
T32$769,232 · 1
U24$428,127 · 1
Top collaborators
- Marc S Greenblatt7 shared
- Lisa A. Cannon Albright5 shared
- David E. Goldgar5 shared
- Mia Hashibe5 shared
- Melissa Southey5 shared
- Donald E Ayer3 shared
- Sheri L. Holmen3 shared
- Randall Walter Burt2 shared
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesVariantSusceptibility GeneCancer-Predisposing GeneBaseMutationCancer RiskInheritedPredispositionDiagnosisMalignant NeoplasmsGenetic VariantProbabilityMalignant Breast NeoplasmCancer GeneticsGeneticGenetic Predisposition To DiseaseFamilyCase ControlResourcesAllelesOncogenesMassive Parallel SequencingBrca1 Gene
Grant awards (42)
Upgrading rigor and efficiency of germline cancer gene variant classification for the 2020s$552,001
R01 · FY2025 · CA · contact PI
Huntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling (Cancer GEMS) Training Program$268,514
T32 · FY2025 · CA
Upgrading rigor and efficiency of germline cancer gene variant classification for the 2020s$520,538
R01 · FY2024 · CA · contact PI
Huntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling (Cancer GEMS) Training Program$303,786
T32 · FY2024 · CA
InSiGHT-ClinGen Polyposis/Colon Cancer Variant Curation Expert Panel$143,830
U24 · FY2024 · CA
Upgrading rigor and efficiency of germline cancer gene variant classification for the 2020s$538,540
R01 · FY2023 · CA · contact PI
Cloud Enabled, Rigorous, Functional Assay Calibration (CERFAC)$220,416
R01 · FY2023 · CA · contact PI
Huntsman Cancer Institute (HCI) Cancer Genetics, Epigenetics, Models, and Signaling (Cancer GEMS) Training Program$196,932
T32 · FY2023 · CA
InSiGHT-ClinGen Polyposis/Colon Cancer Variant Curation Expert Panel$16,052
U24 · FY2023 · CA
Upgrading rigor and efficiency of germline cancer gene variant classification for the 2020s$590,708
R01 · FY2022 · CA · contact PI
InSiGHT-ClinGen Polyposis/Colon Cancer Variant Curation Expert Panel$268,245
U24 · FY2022 · CA
Common and rare sequence variants in breast cancer risk$583,065
R01 · FY2021 · CA · contact PI
Common and rare sequence variants in breast cancer risk$593,435
R01 · FY2020 · CA · contact PI
Common and rare sequence variants in breast cancer risk$584,508
R01 · FY2019 · CA · contact PI
Exome sequencing for head and neck cancer susceptibility genes$717,394
R01 · FY2018 · DE
Common and rare sequence variants in breast cancer risk$596,399
R01 · FY2018 · CA · contact PI
Exome sequencing for head and neck cancer susceptibility genes$713,717
R01 · FY2017 · DE
Common and rare sequence variants in breast cancer risk$585,500
R01 · FY2017 · CA · contact PI
Exome sequencing for head and neck cancer susceptibility genes$714,205
R01 · FY2016 · DE
Massively Parallel Sequencing for Familial Colon Cancer Genes$578,855
R01 · FY2016 · CA · contact PI
Classifying DNA Mismatch Repair Gene Variants of Unknown Significance$541,918
R01 · FY2016 · CA · contact PI
Exome sequencing for head and neck cancer susceptibility genes$741,441
R01 · FY2015 · DE
Massively Parallel Sequencing for Familial Colon Cancer Genes$589,460
R01 · FY2015 · CA · contact PI
Classifying DNA Mismatch Repair Gene Variants of Unknown Significance$520,565
R01 · FY2015 · CA · contact PI
A comprehensive approach to breast cancer susceptibility across the risk spectrum$19,878
R01 · FY2015 · CA
Molecular and Clinical Approaches to Colon Cancer Precursors$2,047,627
P01 · FY2014 · CA · contact PI
Exome sequencing for head and neck cancer susceptibility genes$731,743
R01 · FY2014 · DE
Massively Parallel Sequencing for Familial Colon Cancer Genes$575,663
R01 · FY2014 · CA · contact PI
A comprehensive approach to breast cancer susceptibility across the risk spectrum$573,230
R01 · FY2014 · CA
Classifying DNA Mismatch Repair Gene Variants of Unknown Significance$540,980
R01 · FY2014 · CA · contact PI
Molecular and Clinical Approaches to Colon Cancer Precursors$2,032,829
P01 · FY2013 · CA
Classifying DNA Mismatch Repair Gene Variants of Unknown Significance$597,299
R01 · FY2013 · CA · contact PI
Massively Parallel Sequencing for Familial Colon Cancer Genes$566,708
R01 · FY2013 · CA · contact PI
A comprehensive approach to breast cancer susceptibility across the risk spectrum$497,212
R01 · FY2013 · CA
Massively Parallel Sequencing for Familial Colon Cancer Genes$598,594
R01 · FY2012 · CA · contact PI
A comprehensive approach to breast cancer susceptibility across the risk spectrum$544,870
R01 · FY2012 · CA
A comprehensive approach to breast cancer susceptibility across the risk spectrum$572,952
R01 · FY2011 · CA
COMMON AND RARE SEQUENCE VARIANTS IN BREAST CANCER RISK$423,703
R01 · FY2011 · CA · contact PI
COMMON AND RARE SEQUENCE VARIANTS IN BREAST CANCER RISK$459,385
R01 · FY2010 · CA · contact PI
COMMON AND RARE SEQUENCE VARIANTS IN BREAST CANCER RISK$439,960
R01 · FY2009 · CA · contact PI
COMMON AND RARE SEQUENCE VARIANTS IN BREAST CANCER RISK$424,800
R01 · FY2008 · CA · contact PI
COMMON AND RARE SEQUENCE VARIANTS IN BREAST CANCER RISK$238,676
R01 · FY2007 · CA · contact PI